Whole-genome testing added to standard testing for MDS
Part of Blood & lymphatic clinical trials.
This study checks whether adding whole-genome sequencing (a deeper look at DNA) alongside standard genomic tests helps in evaluating myelodysplastic syndrome (MDS). It aims to see if this extra testing is useful and acceptable during routine care—especially for people newly being worked up for MDS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an MDS diagnosis, or your doctor suspects new MDS and plans routine testing
- You’re being seen as an outpatient (not an inpatient stay)
- You are not already on “disease-modifying” MDS treatments like lenalidomide or chemotherapy-like drugs that change the disease
- You’re at least 18 years old
- You can understand the study and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether adding whole genome sequencing (reading a person’s DNA more broadly) alongside standard genetic tests improves the diagnosis process for AML or MDS. It may help doctors decide on the best next steps when AML/MDS is suspected.
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study collects and stores blood and bone marrow samples from young people with certain blood cancers so doctors can do genetic (“genomic”) testing now and in the future. It may help improve understanding of the disease and support better matching of care for patients.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
Hear when a new Whole Genome Sequencing trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.